StreetInsider.com News Articles

Wedbush Starts Immunic Inc. (IMUX) at Outperform

Mon, 17 Aug 2026 07:06:16 -0400

(Updated - August 17, 2026 7:06 AM EDT)

Wedbush analyst Martin Fan initiates coverage on Immunic Inc. (NASDAQ: IMUX) with a Outperform rating and a price target of $45.00.

The analyst comments "IMUX is a clinical-stage biopharmaceutical company developing immune modulators for immunology and inflammation (I&I). Lead program vidofludimus calcium (IMU-838) is a dual-action selective DHODH inhibitor and Nurr1 activator in Phase 3 development for relapsing multiple sclerosis (RMS), with Phase 2 data also supporting activity in both relapsing and progressive forms of MS. Patient followup indicates high durability of response and an advantageous safety profile relative to other approved drug classes,

Wedbush Starts Immunic Inc. (IMUX) at Outperform

Mon, 17 Aug 2026 07:06:16 -0400

(Updated - August 17, 2026 7:06 AM EDT)

Wedbush analyst Martin Fan initiates coverage on Immunic Inc. (NASDAQ: IMUX) with a Outperform rating and a price target of $45.00.

Form SCHEDULE 13G IMMUNIC, INC. Filed by: ORBIMED ADVISORS LLC

Fri, 14 Aug 2026 17:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26932989.html

Form SCHEDULE 13G IMMUNIC, INC. Filed by: ORBIMED ADVISORS LLC

Fri, 14 Aug 2026 17:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26932989.html

Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932177.html

Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932177.html

Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Commodore Capital LP

Fri, 14 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260814/26931172.html

Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Commodore Capital LP

Fri, 14 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260814/26931172.html

Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Soleus Capital Master Fund, L.P.

Thu, 13 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26917376.html

Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Soleus Capital Master Fund, L.P.

Thu, 13 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26917376.html

Form S-8 IMMUNIC, INC.

Wed, 12 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260812/26912778.html

Form S-8 IMMUNIC, INC.

Wed, 12 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260812/26912778.html

Form 8-K IMMUNIC, INC. For: Aug 06

Tue, 11 Aug 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26901272.html

Form 8-K IMMUNIC, INC. For: Aug 06

Tue, 11 Aug 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26901272.html

Form 10-Q IMMUNIC, INC. For: Jun 30

Tue, 11 Aug 2026 06:59:00 -0400

si-local-file:///var/storage/secattach/20260811/26900998.html

Form 10-Q IMMUNIC, INC. For: Jun 30

Tue, 11 Aug 2026 06:59:00 -0400

si-local-file:///var/storage/secattach/20260811/26900998.html

Immunic Inc. (IMUX) Tops Q2 EPS by 43c

Tue, 11 Aug 2026 06:40:52 -0400

Immunic Inc. (NASDAQ: IMUX) reported Q2 EPS of ($0.80), $0.43 better than the analyst estimate of ($1.23).

For earnings history and earnings-related data on Immunic Inc. (IMUX) click here.

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 06:30:00 -0400

– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness –

– Pivotal Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis on Track, with Top-Line Data Expected by End of 2026 –

– Continued Preparations for Phase 3 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis, with Initiation Planned Later This Year –

NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Immunic,

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 06:30:00 -0400

– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness –
– Pivotal Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis on Track, with Top-Line Data Expected by End of 2026 –
– Continued Preparations for Phase 3 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis, with Initiation Planned Later This Year –
NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Immunic,

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 06:30:00 -0400

– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness –
– Pivotal Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis on Track, with Top-Line Data Expected by End of 2026 –
– Continued Preparations for Phase 3 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis, with Initiation Planned Later This Year –
NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Immunic,

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 06:30:00 -0400

– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness –
– Pivotal Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis on Track, with Top-Line Data Expected by End of 2026 –
– Continued Preparations for Phase 3 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis, with Initiation Planned Later This Year –
NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Immunic,

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 06:30:00 -0400

– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness –
– Pivotal Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis on Track, with Top-Line Data Expected by End of 2026 –
– Continued Preparations for Phase 3 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis, with Initiation Planned Later This Year –
NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Immunic,

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 06:30:00 -0400

– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness –
– Pivotal Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis on Track, with Top-Line Data Expected by End of 2026 –
– Continued Preparations for Phase 3 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis, with Initiation Planned Later This Year –
NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Immunic,

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 06:30:00 -0400

– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness –
– Pivotal Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis on Track, with Top-Line Data Expected by End of 2026 –
– Continued Preparations for Phase 3 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis, with Initiation Planned Later This Year –
NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Immunic,

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 06:30:00 -0400

– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness –
– Pivotal Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis on Track, with Top-Line Data Expected by End of 2026 –
– Continued Preparations for Phase 3 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis, with Initiation Planned Later This Year –
NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Immunic,